# Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma

## TL;DR

A patient with non-Hodgkin’s lymphoma was successfully treated with a new type of CAR T-cell therapy targeting both CD20 and CD30, showing promising results with no major side effects.

## Contribution

A novel bispecific CAR T-cell therapy targeting CD20 and CD30 is introduced and shown to be effective in a patient with non-Hodgkin’s lymphoma.

## Key findings

- The patient achieved complete metabolic remission after the first CAR T-cell infusion.
- No cytokine release syndrome or neurotoxicity was observed during treatment.
- Disease-free survival exceeded 12 months following consolidation therapy.

## Abstract

CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting alternative antigens. To address this issue, we developed a CD20-directed CAR T incorporated with an additional CD30-directed binder to enhance cytotoxicity toward cancer cells. Here, we report that a patient with bulky transformed follicular lymphoma was successfully treated with CD20/CD30-directed CAR-T cells. The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart. Complete metabolic remission was achieved 1 month after the first infusion without evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The second dose was given as a consolidation therapy with sustained disease-free survival exceeding 12 months to date. The report underscores the promising therapeutic potential and safety profile of CD20/CD30-directed CAR T-cell therapy.

https://www.clinicaltrials.gov, identifier NCT06756321.